Institute For Clinical Pharmacodynamics, Inc.

Institute For Clinical Pharmacodynamics, Inc., based in Schenectady, New York, delivers pharmacometric analysis, pharmacokinetic-pharmacodynamic modeling, and regulatory science research to the Department of Health and Human Services as a prime contractor, operating exclusively on full-and-open awards with no set-aside designations. The firm is a for-profit, minority-owned organization competing on merit-based federal R&D vehicles in biotechnology and life sciences research (NAICS 541714 and 541715; PSC AJ11).

The vendor's customer base concentrates entirely within HHS. The National Institute of Allergy and Infectious Diseases (NIAID) anchors 99% of combined potential value across the portfolio (2 awards, $146.6 million), while the Food and Drug Administration accounts for the remaining 1% volume on a smaller dollar base (5 awards, $1.4 million combined potential value). This extreme concentration on NIAID reflects the vendor's position on a $146.3 million Pre-Clinical Models of Infectious Diseases IDIQ awarded July 15, 2024, running through July 14, 2031, which covers Task Area C for animal model studies, pathogen production and characterization, and evaluation of candidate countermeasures against RNA viruses with pandemic potential, antimicrobial-resistant infections, and emerging pathogens. A September 25, 2026 delivery order under this IDIQ for pharmacokinetic-pharmacodynamic analysis of mouse model efficacy and PK data for antibacterial compounds carries a $333,240 ceiling and runs through July 2031. On the FDA side, the vendor has executed five definitive contracts for pharmacometric research and modernized susceptibility guidance development: a $325,000 award (August 1, 2026) for daptomycin and enterococcus species susceptibility guidance, a $248,553 award (August 19, 2024) for nitrofurantoin dosing guidance using dynamic urinary tract infection modeling, and three prior contracts completed or nearing completion focused on ampicillin, vancomycin, and sulfamethoxazole-trimethoprim.

Award activity is episodic rather than sustained — two awards in 2022, one in 2023, two in 2024, and two in 2026 — with only $1.5 million obligated against $148.1 million combined potential value, reflecting early-stage execution on the large NIAID IDIQ. One award (the FDA daptomycin contract) reaches ultimate completion within the next twenty-four months at $325,000, representing modest near-term recompete exposure. The vendor operates exclusively as a prime across this portfolio and does not subcontract work; Service Contract Inventory data show minimal federal invoicing activity to date, with only 1.0 FTE reported as a named subcontractor role in FY2024, indicating the vendor's primary revenue is routed through R&D contracts rather than service-contract vehicles. The vendor's capability portfolio centers on pharmacometric modeling, susceptibility testing guidance, regulatory science support, and infectious disease preclinical research, with all work performed in Schenectady, NY for HHS missions in regulatory science and pandemic-preparedness research.